FDA will not approve any new psychedelic NDA in 2026; at least one REMS-heavy conditional pathway is proposed instead.

The FDA (the US drug regulator) won't fully approve any psychedelic medicine in 2026 — too many scientific questions remain unanswered. Instead, the FDA may propose a special framework that would allow limited, heavily supervised use while gathering more safety data. Think of it like a provisional driver's license with lots of restrictions. This matters because it would give patients some access while keeping tight guardrails in place.

My job is patient protection. Mechanistic gaps and functional-unblinding concerns persist. Conditional/REMS frameworks let us advance without abandoning rigor.